Physician profile
Jared Spoons
NPI 1174083398
$3,272.66
in general payments reported to CMS, 2019-2025
21 companies · $872 in 2025
The $872 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.22 · 2021: $12.71 · 2022: $234 · 2023: $971 · 2024: $1,166 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,008.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $551.16 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $499.16 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $360.51 | 2022-2025 | |
| Abbvie INC. | $324.00 | 2024-2025 | |
| Lilly USA, LLC | $285.17 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $247.62 | 2022-2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $220.66 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Amgen INC. | $157.31 | 2023-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals Lp | $122.12 | 2024-2025 | Airsupra, Enhertu |
| Novartis Pharmaceuticals Corporation | $83.73 | 2024 | |
| Phathom Pharmaceuticals, INC. | $76.02 | 2025 | Voquezna |
| Astellas Pharma US INC | $71.70 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.94 | 2024-2025 | Ofev, Jardiance |
| Dynavax Technologies Corporation | $44.96 | 2024 | Heplisav-B |
| Otsuka America Pharmaceutical, INC. | $30.48 | 2022-2024 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $27.72 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $27.60 | 2023 | Xarelto |
| Boston Scientific Corporation | $27.51 | 2025 | Eluvia |
| Cook Medical LLC | $20.63 | 2024 | Zenith |
| Eisai INC. | $19.44 | 2025 | |
| Mylan Specialty L.P. | $17.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Spoons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.